Effects of LY354740, a Novel Glutamatergic Metabotropic Agonist, on Nonhuman Primate Hypothalamic-Pituitary-Adrenal Axis and Noradrenergic Function

@article{Coplan2001EffectsOL,
  title={Effects of LY354740, a Novel Glutamatergic Metabotropic Agonist, on Nonhuman Primate Hypothalamic-Pituitary-Adrenal Axis and Noradrenergic Function},
  author={Jeremy D Coplan and Sanjay J. Mathew and E. Smith and Ronald C. Trost and Bruce A. Scharf and J M Martinez and Jack M. Gorman and James A. Monn and Darryle D. Schoepp and Leonard A. Rosenblum},
  journal={CNS Spectrums},
  year={2001},
  volume={6},
  pages={607 - 617}
}
Abstract The search for novel anxiolytics and antidepressants has focused on compounds with the potential to reduce excessive hypothalamic-pituitary-adrenal (HPA) axis activity. L-glutamate, an excitatory neurotransmitter ubiquitously present within the central nervous system, conceivably plays an important role in activating the neural sites involved in stress modulation. Deactivation of the HPA axis by glutamatergic neurotransmission modulation may represent a novel therapeutic approach… Expand
LY354740, an mGlu2/3 Receptor Agonist as a Novel Approach to Treat Anxiety/Stress
TLDR
Early clinical results with LY354740 have demonstrated safety and efficacy in a human anxiety model (panic provocation induced by CO 2 challenge), and data indicate mGlu2/3 receptor agonists such as LY 354740 represent a promising new approach for treatment of anxiety and stress-related disorders in humans. Expand
Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs.
TLDR
Data has been accumulated, indicating that antagonists of group II mGlu receptors have an antidepressant potential and ligands of these receptors, both agonists and antagonists, may have an anxiolytic-like and antidepressant-like potential. Expand
New perspectives in glutamate and anxiety
TLDR
It is established that glutamate neurotransmission and polyaminergic system play a fundamental role in the onset of anxiety-related disorders and may open the way for new drugs that may help to treat these conditions. Expand
Molecular targets in the treatment of anxiety
TLDR
Current views on both traditional and new molecular targets in the treatment of anxiety are reviewed, realizing that the ultimate challenge in effective anxiolytic drug development may be achieving specificity in brain regions important in generating and sustaining anxiety. Expand
Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: Focus on pharmacology and preclinical translational models
TLDR
How these pathways are involved in fear circuitry of the brain and compare the strength of therapeutic rationale as well as progress towards pharmacological validation of the glutamate pathway towards the treatment of anxiety disorders are discussed, with a particular focus on metabotropic and ionotropic glutamate receptors. Expand
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
TLDR
This review highlights the best studied mGluR strategies for psychiatry, based on human molecular genetics, studies in animal models and preliminary clinical trials, and describes the potential value of mGLUR2 and mGlamR5 agonists and positive allosteric modulators for the treatment of schizophrenia. Expand
Advances in the treatment of anxiety: Targeting glutamate
TLDR
As this glutamatergic system is showing promise as a final common pathway in the pathogenesis of anxiety disorders, it may be able to employ glutamate-specific neuroimaging techniques to both guide treatment decisions and present reliable objective biomarkers for treatment efficacy. Expand
Developmental expression of mGlu2 and mGlu3 in the mouse brain.
TLDR
These studies provide a foundation for future research seeking to parse out the roles of mGLU2 from mGlu3, paving the way for better understanding of how these receptors regulate activity in the brain. Expand
Ligation of metabotropic glutamate receptor 3 (Grm3) ameliorates lupus-like disease by reducing B cells.
TLDR
Results suggest that activation of Grm3 ameliorates lupus-like disease in mice by reducing B cell numbers, and identifies a novel potential target for the treatment of autoimmune diseases. Expand
Glutamate receptors in domestication and modern human evolution
TLDR
Evidence suggests an important role for kainate and metabotropic receptors in regulating hypothalamic-pituitary-adrenal axis excitation, and a mechanistic account of their actions in attenuating the stress response is provided. Expand
...
1
2
...

References

SHOWING 1-10 OF 26 REFERENCES
Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors.
TLDR
A functional role for group II mGluRs in fear/anxiety responses in animals is indicated and compounds in this class may be beneficial in the treatment of anxiety-related disorders in humans without the side effects seen with currently prescribed medications. Expand
Potent, stereoselective, and brain region selective modulation of second messengers in the rat brain by (+)LY354740, a novel group II metabotropic glutamate receptor agonist
TLDR
Data indicate that LY354740 is a highly potent, efficacious, and selective Group II mGlu receptor (mGlu 2/3) agonist in the rat brain. Expand
Uncoupling of the Noradrenergic-Hypothalamic-Pituitary-Adrenal Axis in Panic Disorder Patients
TLDR
Suboptimal NA regulation of the HPA axis in PD patients is suggested, with pathophysiological implications particularly prominent during periods of stress-induced activation of the two systems. Expand
The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal
TLDR
Results indicate mGlu2/3 receptor agonists can attenuate the morphine-withdrawal-induced activation of LC neurons and many behavioral signs of morphine withdrawal; and may have therapeutic effects in man for the treatment of opiate withdrawal. Expand
In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats
TLDR
It is demonstrated that LY354740 blocks the evoked release of endogenous excitatory amino acids, and a role for group II mGluRs in presynaptic modulation of glutamate neuronal transmission in vivo is indicated. Expand
LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats
TLDR
Data support the functional role of mGluR agonists in nicotine withdrawal and indicate that LY354740 may be efficacious in reducing the symptoms associated with nicotine withdrawal during smoking cessation in humans. Expand
Alpha 2-adrenergic receptor function in depression. The cortisol response to yohimbine.
TLDR
The abnormally increased cortisol response to the alpha 2-antagonist yohimbine suggests a relative subsensitivity of postsynapticalpha 2-adrenergic receptors in depression. Expand
Metabotropic glutamate receptor in vasopressin, CRF and VIP hypothalamic neurones
TLDR
The results support the view that the excitatory transmitter glutamate may directly influence AVP, CRF and VIP neurones of the three hypothalamic cell groups. Expand
LY354740 is a Potent and Highly Selective Group II Metabotropic Glutamate Receptor Agonist in Cells Expressing Human Glutamate Receptors
TLDR
LY354740 is a highly potent, efficacious and selective group II (mGlu2/3) receptor agonist, useful to explore the functions of these receptors in situ. Expand
Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders.
TLDR
Grown nonhuman primates who were exposed as infants to adverse early rearing conditions were studied to determine if long-term alterations of CRF neuronal systems had occurred following the early stressor. Expand
...
1
2
3
...